middle.news
Firebrick Pharma Reports $3.06 Million Loss with Early Nasodine Commercialisation Progress
5:23pm on Monday 31st of August, 2026 AEST
•
Healthcare
Read Story
Firebrick Pharma Reports $3.06 Million Loss with Early Nasodine Commercialisation Progress
5:23pm on Monday 31st of August, 2026 AEST
Key Points
FY26 net loss of $3.06 million on revenues down 64%
Nasodine product sales growing in US and Southeast Asia
Regulatory approvals secured in Indonesia and pending in Philippines
Raised $3.17 million via share placements during the year
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Firebrick Pharma (ASX:FRE)
OPEN ARTICLE